Lundbeck, Drug Prices & Medicare Spending
Lundbeck manufactures 3 drugs tracked by Medicare Part D with total spending of $590.0M.
Lundbeck Drugs, Ranked by Medicare Spending
| # | Drug | Generic Name | Cost/Claim | Generic? |
|---|---|---|---|---|
| 1 | Vyepti | Eptinezumab | $944.00 | Yes |
| 2 | Onfi | Clobazam | $718.00 | Yes |
| 3 | Sabril | Vigabatrin | $4,238.00 | Yes |
Frequently Asked Questions
Lundbeck manufactures 3 drugs tracked by Medicare Part D, with total annual spending of $590.0M.
Sabril (Vigabatrin) is the most expensive at $4,238.00 per claim.
3 of 3 Lundbeck drugs (100%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.
For this entity, the underlying data on this page comes from CMS Medicare Part D Drug Spending data. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
Every number on this page links back to CMS Medicare Part D Drug Spending data; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.
Source: CMS Medicare Part D Spending, 2026.